GlassScriptPhysician profile
Dana C Point
NPI 1659665560
$7,545.70
in general payments reported to CMS, 2019-2025
49 companies · $1,921 in 2025
The $1,921 reported for 2025 was more than what 79% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $97.37 · 2021: $742 · 2022: $1,393 · 2023: $1,638 · 2024: $1,753 · 2025: $1,921.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,277 · Education: $35.06.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,277.46 |
| Education | $35.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $997.85 | 2021-2025 | Erleada |
| Astellas Pharma US INC | $958.60 | 2021-2025 | Xtandi, Veozah, Myrbetriq |
| Dendreon Pharmaceuticals LLC | $883.03 | 2021-2025 | Provenge |
| Sumitomo Pharma America, INC. | $549.33 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $504.04 | 2021-2025 | |
| 180 Medical, INC. | $266.80 | 2021-2025 | Gentlecath, Cure Catheter, Gentlecath Glide |
| Antares Pharma, INC. | $247.85 | 2021-2025 | Xyosted, Nocdurna, Tlando |
| Ferring Pharmaceuticals INC. | $217.98 | 2024-2025 | Adstiladrin |
| Myriad Genetic Laboratories, INC. | $216.02 | 2021-2022 | |
| Abbvie INC. | $209.69 | 2023-2025 | |
| Myovant Sciences INC. | $175.74 | 2021-2022 | |
| Accord Healthcare, INC. | $156.24 | 2022-2024 | |
| Endo USA, INC. | $151.67 | 2024-2025 | Xiaflex, Aveed |
| Astrazeneca Pharmaceuticals LP | $148.08 | 2022-2025 | Lynparza, Imfinzi, Wainua |
| Urovant Sciences INC | $146.69 | 2021-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dana Point listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.